Premium
Biological Evaluation of the NIR‐Emissive Ruby Analogue [Cr(ddpd) 2 ][BF 4 ] 3 as a Photodynamic Therapy Photosensitizer
Author(s) -
Basu Uttara,
Otto Sven,
Heinze Katja,
Gasser Gilles
Publication year - 2019
Publication title -
european journal of inorganic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.667
H-Index - 136
eISSN - 1099-0682
pISSN - 1434-1948
DOI - 10.1002/ejic.201801023
Subject(s) - photodynamic therapy , photosensitizer , cytotoxicity , chromium , chemistry , fluorescence , hela , phototoxicity , solubility , glioblastoma , photochemistry , nuclear chemistry , cancer research , cell , in vitro , biochemistry , organic chemistry , medicine , optics , physics
Photodynamic therapy relies on the bioavailability of photosensitizers with suitable photophysical, chemical, and biochemical properties. Although the photophysical properties, stability, and high water solubility of the chromium(III) complex [Cr(ddpd) 2 ][BF 4 ] 3 (ddpd = N , N′ ‐dimethyl‐ N , N′ ‐dipyridin‐2‐ylpyridine‐2,6‐diamine) are very favorable, its photocytotoxicity against cancerous and non‐cancerous cell lines has not yet been elucidated. We now report the cytotoxicity and photocytotoxicity of the complex [Cr(ddpd) 2 ][BF 4 ] 3 against human cervical cancer cells, human primary glioblastoma cells, human glioblastoma astrocytoma cells, and non‐cancerous retinal pigment epithelium cells.